New York, NY - Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online ...
A PSA test can screen for prostate cancer or show how well treatment worked. Find out when you'll have this test, and what your results could mean.
Dosage du PSA, biopsie, cancer et hypertrophie bénigne de la prostate en France Prostate-specific antigen (PSA) testing is high in France. The aim of this study was to estimate their frequency and those of biopsy and newly diagnosed ca... P Tuppin,S Samson,A Fagot-Campagna,... - 《...
However, test- ing total PSA (tPSA) levels to decide which patients should undergo a biopsy has been found to lead to high rates of false- negative and false-positive results. In men with false-negative results, cancer may be missed. Men with false-positive results may undergo unwarranted ...
If your PSA is elevated, other tests may help decide if a biopsy is needed. If cancer is suspected, a biopsy can confirm it, and a wide range of approaches can be considered: from active surveillance (just monitoring the tests and seeing if the cancer grows), to zapping only the par...
PSA and PSA velocity (PSAV, rate of PSA change over time) are biomarkers for diagnosis and prognosis of prostate cancer. Men who are at high risk for prostate cancer also have associated comorbidities for which they are taking NSAIDs and statins for long periods; therefore, it is important ...
nPSA is a strong independent predictor of freedom from PSA failure and PFS in patients with low and intermediate-risk localized prostate cancer treated with RT alone. Longer follow-up and larger patient numbers are required to confirm these observations. 展开 ...
Long-term prediction of prostate cancer: prostate- specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, repre- sentative, unscreened population. J Clin Oncol. 2008;26:835-84...
MP86-14 DOES A SECOND CONFIRMATORY PSA ABOVE 4.0NG/ML LEAD TO THE DIAGNOSIS OF MORE CLINICALLY SIGNIFICANT PROSTATE CANCER?1. Establish independent SWOG operations at the Portland VA Medical Center. 2. Establish processes that enable site to maintain accrual goals for site through life of project...
Comments on the controversial issue of prostate-specific antigen (PSA) screening for prostate cancer. Data on and possible explanations for the decline in the prostate cancer mortality rate in the U.S.; Reference to a study by the urology department of the University of Innsbruck, Austria that ...